Boehringer Ingelheim comments the nevirapine production for Rwanda by Apotex
- Details
- Category: Boehringer Ingelheim
On Sept. 19th, 2007, the Canadian Patent Office (CIPO) granted an authorisation to the Canadian generic manufacturer Apotex Inc. for the production of a certain volume of APO-TRIOVIR for export into Rwanda. This HIV medicament is a fixed dose combination of three active ingredients, one of which is nevirapine patented for Boehringer Ingelheim.
GSK applies for licence to market OTC weight loss product In Europe
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced its marketing application for non-prescription orlistat 60mg for weight loss has been accepted for review by the European Agency for the Evaluation of Medicinal Products (EMEA). Orlistat 60 mg was approved for non-prescription sale in the US by the FDA in February 2007 for use by overweight adults in conjunction with a reduced-calorie, low-fat dietand went on sale there in June 2007 under the brand name alli™.
Herceptin eradicates tumours and may reduce the need for mastectomies
- Details
- Category: Roche
New data show that the addition of Herceptin (trastuzumab) to chemotherapy prior to breast cancer surgery (neoadjuvant therapy) completely eradicates tumours in nearly three times as many women with inflammatory HER2-positive breast cancer compared to chemotherapy alone. Inflammatory breast cancer is a rare, but highly aggressive form of the disease - the tumours spread quickly, often leading to the need for total mastectomies, and it has a worse outlook than other breast cancers.
Bionas Signs Service Contract with Solvay Pharmaceuticals
- Details
- Category: Business
Bionas GmbH, a specialist for in vitro profiling of cellular metabolic activity, announced that it has signed a service contract with Solvay Pharmaceuticals GmbH (Hannover, Germany). The contract covers the metabolic profiling of several drug candidates identified in the context of Solvay's obesity research program. Financial details were not disclosed.
Positive Phase 2 Results for the VEGF Trap-Eye
- Details
- Category: Bayer
Bayer HealthCare and development partner Regeneron Pharmaceuticals, Inc. today announced positive results from a Phase 2 study evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD), one of the leading causes of blindness in adults. The VEGF Trap-Eye met both the primary study endpoint of a statistically significant reduction in retinal thickness and the key secondary endpoint of improvement of visual acuity after 12 weeks.
Novartis and Massachusetts Institute of Technology (MIT) in new partnership
- Details
- Category: Novartis
Novartis and the Massachusetts Institute of Technology have launched a long-term research collaboration aimed at transforming the way pharmaceuticals are produced. The 10-year partnership, known as the Novartis-MIT Center for Continuous Manufacturing, will work to develop new technologies that could replace the conventional batch-based system in the pharmaceuticals industry - which often includes many interruptions and work at separate sites - with continuous manufacturing processes from start to finish.
Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced that it has finalized a civil settlement agreement with the United States Department of Justice ("DOJ") and the Office of the United States Attorney for the District of Massachusetts resolving the previously disclosed investigations that began several years ago involving the company's drug pricing, and sales and marketing activities.
More Pharma News ...
- Takeda to Sponsor Berlin Marathon 2007
- Prix Galien USA Names HUMIRA Best Biotechnology Product
- Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
- Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer
- Start of the TALENT Study - a Unique Antihypertensive Study in Europe
- Nycomed and NPS Pharmaceuticals Announce Licensing Agreement for GATTEX™
- FDA Accepts sNDA for Expanded Use of Angiomax®